TSE:ARZ - Aralez Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.33 +0.02 (+6.45 %)
(As of 07/19/2018 04:00 PM ET)
Previous CloseC$0.31
Today's RangeC$0.30 - C$0.34
52-Week RangeC$0.29 - C$3.72
Volume117,000 shs
Average Volume69,698 shs
Market CapitalizationC$119.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Receive ARZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Gold
Sub-IndustryN/A
SectorBasic Materials
SymbolTSE:ARZ
CUSIPN/A
Phone+1-905-8761118

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-100.42%
Return on Equity-146.16%
Return on Assets-20.43%

Miscellaneous

EmployeesN/A
Outstanding Shares67,194,000
Market CapC$119.34

Aralez Pharmaceuticals (TSE:ARZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc (TSE:ARZ) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.05. The firm had revenue of $48.14 million for the quarter, compared to analysts' expectations of $40.80 million. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%. View Aralez Pharmaceuticals' Earnings History.

When is Aralez Pharmaceuticals' next earnings date?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

What is the consensus analysts' recommendation for Aralez Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aralez Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Mr. Michael Kaseta, Chief Financial Officer (Age 42)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

Has Aralez Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARZ stock has been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned news stories about the company an impact score of 45.15 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Aralez Pharmaceuticals?

Shares of ARZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of ARZ stock can currently be purchased for approximately C$0.33.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of C$119.34 million.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.


MarketBeat Community Rating for Aralez Pharmaceuticals (TSE ARZ)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.